Clostridium difficile and Clostridium perfringens researchNosocomial Infections in ICUAntibiotic Resistance in BacteriaGastrointestinal motility and disordersHemoglobinopathies and Related Disorders
Publications
13
Citations
222
Est. group size
—
Recurring co-author estimate
Active years
10
Publishing since 2016
Publication cadence
Publications per year over the last 10 years — averaging 0.6/year recently
Recent publications
- Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial
The Lancet Infectious Diseases · 2019
- SYN-004 (Ribaxamase), an Orally Administered β-Lactamase for Prevention of Clostridium Difficile Infection in Patients Treated with Intravenous β-Lactam Antibiotics: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study
SSRN Electronic Journal · 2018
- The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies
Antimicrobial Agents and Chemotherapy · 2017
- Development of a Modified-Release Formulation of Lovastatin Targeted to Intestinal Methanogens Implicated in Irritable Bowel Syndrome With Constipation
Journal of Pharmaceutical Sciences · 2017
- SYN-004 (ribaxamase) prevents New Onset Clostridium difficile Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study
Open Forum Infectious Diseases · 2017
- SYN-004 (Ribaxamase), an Oral β-Lactamase, Prevented Clostridium Difficile Infection and Protected Patients from Colonization by Antimicrobial Resistant Pathogens by Preserving Gut Microbiome Diversity in a Phase 2B Clinical Trial
Gastroenterology · 2017
- Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies
Clinical Drug Investigation · 2016
- Su1210 SYN-010, a Proprietary Modified-Release Formulation of Lovastatin Lactone, Lowered Breath Methane and Improved Stool Frequency in Patients With IBS-C: Results of a Multi-Center Randomized Double-Blind Placebo-Controlled Phase 2a Trial
Gastroenterology · 2016
- SYN-010 Modified-Release Lovastatin Does Not Significantly Alter Lipid Parameters at Doses that Reduce Methane and Alleviate Symptoms in Patients Suffering Irritable Bowel Syndrome with Constipation (IBS-C)
The American Journal of Gastroenterology · 2016
- The Oral β-Lactamase SYN-004, Designed to Protect the Gut Microbiome from Biliary Excreted IV Antibiotics, Efficiently Degrades Intestinal Ceftriaxone in Two Phase 2a Clinical Trials
Open Forum Infectious Diseases · 2016
Publishes in
- Gastroenterology×2
- Open Forum Infectious Diseases×2
- Antimicrobial Agents and Chemotherapy×1
- The Lancet Infectious Diseases×1
- Clinical Drug Investigation×1
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 9, 2026.
Claim or correct this profile